Goldman Sachs raised the firm’s price target on Teva (TEVA) to $35 from $31 and keeps a Buy rating on the shares.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TEVA:
- Sagimet Biosciences, TAPI announce global license agreement for resmetirom
- Teva price target raised to $35 from $28 at JPMorgan
- Insider Selling Frenzy: AppLovin, Teva, AST SpaceMobile, MongoDB, and Western Digital Stocks in Focus!
- Teva Pharmaceutical Extends Revolving Facility Agreement
- FTC investigation prompts Teva request for removal of patents from Orange Book